Abstract
Albumin is a versatile drug carrier in anti-cancer drug delivery system and it also has an actively targeting capacity to tumors. Recently, nanoparticle albumin-bound (nab™) paclitaxel (nab-paclitaxel; Abraxane®) has been approved in 2006 for use in patients with metastatic breast cancer who have failed in the combination chemotherapy, and so the nab-technology has attracted much interest in the anti-cancer drug delivery system. The details about the preparation, characterization and evaluation of nab-paclitaxel (ABI-007) are discussed. The pharmacokinetics, pharmacodynamics and the clinical trials of ABI-007 are also reviewed. Furthermore, the recent applications of nabtechnology in the anti-cancer drug delivery systems are summarized by virtue of the patents pertaining to nab-technology. To sum up, nab-technology has a great potential of being applied extensively in the field of anti-cancer agents delivery in the future in order to acquire the good safety and better therapeutical effect.
Keywords: Nab- technology, anti-cancer drug, paclitaxel, albumin
Recent Patents on Anti-Cancer Drug Discovery
Title: Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery
Volume: 4 Issue: 3
Author(s): Qiang Fu, Jin Sun, Wenping Zhang, Xiaofan Sui, Zhongtian Yan and Zhonggui He
Affiliation:
Keywords: Nab- technology, anti-cancer drug, paclitaxel, albumin
Abstract: Albumin is a versatile drug carrier in anti-cancer drug delivery system and it also has an actively targeting capacity to tumors. Recently, nanoparticle albumin-bound (nab™) paclitaxel (nab-paclitaxel; Abraxane®) has been approved in 2006 for use in patients with metastatic breast cancer who have failed in the combination chemotherapy, and so the nab-technology has attracted much interest in the anti-cancer drug delivery system. The details about the preparation, characterization and evaluation of nab-paclitaxel (ABI-007) are discussed. The pharmacokinetics, pharmacodynamics and the clinical trials of ABI-007 are also reviewed. Furthermore, the recent applications of nabtechnology in the anti-cancer drug delivery systems are summarized by virtue of the patents pertaining to nab-technology. To sum up, nab-technology has a great potential of being applied extensively in the field of anti-cancer agents delivery in the future in order to acquire the good safety and better therapeutical effect.
Export Options
About this article
Cite this article as:
Fu Qiang, Sun Jin, Zhang Wenping, Sui Xiaofan, Yan Zhongtian and He Zhonggui, Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (3) . https://dx.doi.org/10.2174/157489209789206869
DOI https://dx.doi.org/10.2174/157489209789206869 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNAs Regulate the Epithelial to Mesenchymal Transition (EMT) in Cancer Progression
MicroRNA Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Role of Oxidative Stress Response Elements and Antioxidants in Prostate Cancer Pathobiology and Chemoprevention -- A Mechanistic Approach
Current Medicinal Chemistry Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer
Current Cancer Drug Targets Vitamin D Receptor Agonists, Cancer and the Immune System: An Intricate Relationship
Current Topics in Medicinal Chemistry Proteome Analysis in Hematology Using Capillary Electrophoresis Coupled On-Line to Mass Spectrometry
Mini-Reviews in Medicinal Chemistry Current Concepts in Reprogramming Somatic Cells to Pluripotent State
Current Stem Cell Research & Therapy Identification of Phosphoproteins and their Impact as Biomarkers in Cancer Therapeutics
Current Signal Transduction Therapy Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes
Current Medicinal Chemistry Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Pathophysiology of Erectile Dysfunction
Current Drug Targets Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets Animal Peptides Targeting Voltage-Activated Sodium Channels
Current Pharmaceutical Design Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets